Isomorphic Labs, the Alphabet-affiliated AI drug discovery company, raises $5 billion in a Series C funding round. Multiple outlets say the round is co-led by Greenoaks and Sequoia Capital, with Alphabet’s parent and other investors participating or contributing capital. Coverage frames the fundraising as part of an effort to advance the company’s early drug programs.
Several reports add that the push is aimed at moving candidate drugs toward clinical trials, citing remarks attributed to Isomorphic’s CEO, Demis Hassabis. Others note the timing: the Series C follows an earlier large round about six months earlier, described as $2.1 billion, suggesting continued investor confidence even amid broader AI-sector uncertainty.
Across outlets, the core facts remain consistent—round size, co-leads, and the clinical-trials objective—while details vary in emphasis, such as highlighting Alphabet’s involvement, the company’s background as a DeepMind spin-out, or the competitive context for biotech funding.